Amivantamab and lazertinib \u201csignificantly delayed\u201d time to symptomatic progression (TTSP) compared with osimertinib in patients with previously untreated, advanced, EGFR-mutated non-small cell lung cancer (NSCLC), according to an analysis of the MARIPOSA study.<\/p>\n
Danny Nguyen, MD, of the City of Hope National Medical Center, and colleagues, conducted the analysis and published their findings in the European Journal of Cancer.<\/p>\n
The combination of amivantamab and lazertinib combination therapy previously demonstrated \u201cimproved progression-free survival (PFS) and overall survival (OS)\u201d compared with osimertinib in the MARIPOSA trial, according to the study authors.<\/p>\n
Dr. Nguyen and colleagues explained that the TTSP measure, which \u201cprovides an easily interpretable measure of disease-specific symptom worsening to further support patient experience,\u201d was \u201cintroduced to assess clinical worsening and complement end points that investigate radiographic disease progression and patient-reported outcomes.\u201d<\/p>\n
They quantitatively assessed TTSP as a secondary efficacy end point in MARIPOSA and defined TTSP \u201cas the time from randomization until participants experience disease-specific symptom worsening requiring a clinical intervention or treatment change, or death,\u201d according to the publication. They conducted an exploratory analysis censoring deaths to \u201cevaluate the impact of amivantamab and lazertinib on TTSP considering its established OS benefit against osimertinib,\u201d Dr. Nguyen and colleagues explained.<\/p>\n
The median TTSP was 43.6 months with amivantamab plus lazertinib and was 29.3 months in those receiving osimertinib (hazard ratio [HR], 0.69; 95% CI: 0.57\u20130.83; P<.001) at the final protocol-specified OS analysis, which had a median follow-up of 37.8 months.<\/p>\n
\u201cAmivantamab and lazertinib reduced deaths following a TTSP event compared to osimertinib,\u201d Dr. Nguyen and colleagues explained, noting that \u201ca strong correlation between TTSP and PFS or OS was observed.\u201d<\/p>\n
Based on these findings, Dr. Nguyen and colleagues conclude that TTSP provides \u201ccomplementary insights alongside traditional end points\u201d and that it \u201cenhances understanding of treatment benefit and supports informed clinical decision-making by integrating patient experience.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Amivantamab and lazertinib \u201csignificantly delayed\u201d time to symptomatic progression (TTSP) compared with osimertinib in patients with previously untreated,…\n","protected":false},"author":2,"featured_media":550203,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-550202","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/550202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=550202"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/550202\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/550203"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=550202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=550202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=550202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}